Published in Arthritis Rheum on January 01, 2004
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther (2006) 1.37
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Preliminary identification of core domains for outcome studies in psoriatic arthritis using Delphi methods. Ann Rheum Dis (2005) 1.30
Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis (2006) 1.24
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis (2005) 1.21
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) (2008) 1.12
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis (2009) 1.09
Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis (2005) 1.07
Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis (2004) 1.06
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.05
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther (2010) 0.91
Consensus exercise on domains in psoriatic arthritis. Ann Rheum Dis (2005) 0.90
OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis (2005) 0.84
The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag (2016) 0.83
High-resolution uniform MR imaging of finger joints using a dedicated RF coil at 3T. J Magn Reson Imaging (2010) 0.81
Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis (2007) 0.81
Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris. Clin Dev Immunol (2013) 0.81
Remission criteria and activity indices in psoriatic arthritis. Clin Rheumatol (2014) 0.78
[Psoriatic arthritis. Treatment outcome parameters]. Z Rheumatol (2009) 0.78
Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. Ann Rheum Dis (2006) 0.76
[Outcome parameters for use in psoriatic arthritis]. Z Rheumatol (2006) 0.75
Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 10.39
Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet (2006) 3.86
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Investigation of the cause of death in a gene-therapy trial. N Engl J Med (2009) 3.02
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00
Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2005) 2.71
Patient perspectives on the impact of fibromyalgia. Patient Educ Couns (2008) 2.57
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum (2013) 2.13
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol (2010) 2.06
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 2.02
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Relationship between process and outcome in stroke care. Stroke (2003) 1.70
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis (2005) 1.57
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med (2015) 1.56
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum (2002) 1.50
Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index. J Rheumatol (2010) 1.49
Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol (2013) 1.46
Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol (2010) 1.46
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum (2007) 1.44
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2004) 1.43
Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken) (2014) 1.43
Use of navigation-assisted fluoroscopy to decrease radiation exposure during minimally invasive spine surgery. Spine J (2007) 1.36
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35
An energy supply network of nutrient absorption coordinated by calcium and T1R taste receptors in rat small intestine. J Physiol (2008) 1.29
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum (2010) 1.27
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest (2015) 1.27
Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol (2005) 1.26
Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.25
Outcome domains for studies of acute and chronic gout. J Rheumatol (2009) 1.24
Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther (2011) 1.23
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis (2014) 1.17
Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol (2010) 1.16
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis (2012) 1.15
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
Minimally invasive spine surgery. Spine (Phila Pa 1976) (2010) 1.11
FOOTSTEP: a randomized controlled trial investigating the clinical and cost effectiveness of a patient self-management program for basic foot care in the elderly. J Clin Epidemiol (2003) 1.10
Hydrogen-bonding propensities of sphingomyelin in solution and in a bilayer assembly: a molecular dynamics study. Biophys J (2003) 1.08
The prevalence of foot ulceration in patients with rheumatoid arthritis. Arthritis Rheum (2008) 1.07
Sinus pericranii: dermatologic considerations and literature review. J Am Acad Dermatol (2002) 1.07
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis (2012) 1.05
Outcome measures in psoriatic arthritis. J Rheumatol (2007) 1.05
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol (2007) 1.04
Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). Rheum Dis Clin North Am (2009) 1.03
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum (2009) 1.02
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) (2011) 1.02
Effect of intraocular surgery and ketamine on aqueous and serum cytokines. Mol Vis (2007) 1.01
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum (2004) 1.01
Psoriatic arthritis screening tools. J Rheumatol (2008) 1.00
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol (2009) 1.00
Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res (2003) 1.00
Trace element supplementation after major burns increases burned skin trace element concentrations and modulates local protein metabolism but not whole-body substrate metabolism. Am J Clin Nutr (2007) 1.00
Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum (2007) 1.00
Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol (2009) 0.99
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol (2007) 0.98
Direct measurement of lymphocyte receptor diversity. Nucleic Acids Res (2003) 0.98
The use of bioabsorbable implants in the spine. Spine J (2003) 0.97
Validation of a radiographic damage index in chronic gout. Arthritis Rheum (2007) 0.96
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol (2006) 0.96
Multidisciplinary approach to fibromyalgia: what is the teaching? Best Pract Res Clin Rheumatol (2011) 0.95
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol (2011) 0.95
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol (2009) 0.95
Extracutaneous ultrastructural alterations in pseudoxanthoma elasticum. Ultrastruct Pathol (2003) 0.95
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) (2012) 0.95
Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis (2010) 0.94
Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat (2006) 0.94
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum (2008) 0.94
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol (2014) 0.93
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
PrP antibodies do not trigger mouse hippocampal neuron apoptosis. Science (2012) 0.92
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis (2010) 0.92
Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol (2012) 0.92
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol (2009) 0.91
Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheumatol Suppl (2008) 0.91
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol (2009) 0.91
Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin Arthritis Rheum (2007) 0.91
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol (2014) 0.91
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther (2012) 0.90
Can a short period of micronutrient supplementation in older institutionalized people improve response to influenza vaccine? A randomized, controlled trial. J Am Geriatr Soc (2004) 0.90